PMID- 21354832
OWN - NLM
STAT- MEDLINE
DCOM- 20110628
LR  - 20161125
IS  - 1532-2165 (Electronic)
IS  - 1078-5884 (Linking)
VI  - 41
IP  - 5
DP  - 2011 May
TI  - Endovenous laser ablation (EVLA) to treat recurrent varicose veins.
PG  - 691-6
LID - 10.1016/j.ejvs.2011.01.018 [doi]
AB  - OBJECTIVES: This cohort study assesses the effectiveness and safety of endovenous 
      laser ablation (EVLA) in the management of recurrent varicose veins (RVVS). 
      METHOD: 104 limbs (95 patients) undergoing EVLA for RVVS were grouped according 
      to pattern of reflux. For patients with recurrent SFJ/great saphenous vein (GSV) 
      (Group GR) and SPJ/small saphenous vein (SSV) (Group SR) varicosities ablation 
      rates and QoL (Aberdeen Varicose Vein Severity Scores (AVVSS)) were compared with 
      those for age/sex matched patients undergoing EVLA for primary GSV/SSV dependent 
      varicose veins (Groups GP and SP). RESULTS: In patients with RVVS the axial vein 
      was ablated in 102/104 (98%) limbs whilst 2 GSVs (group GR) partially recanalised 
      by 3 months (GSV ablated in 49/51 (96%) limbs versus 50/51 (98%) limbs in GP [p = 
      0.2]). Improvements in AVVSS at 3 months (median GR: 14.2 (inter-quartile range 
      (IQR) 10.2-18.9) to 3.2(1.2-6.4), p < 0.001; GP: median 15.9(IQR 11.4-22.7) to 
      3.8(1.1-5.6), p < 0.001, Mann-Whitney u-test) were similar (78% versus 76%, p = 
      0.23). The SSV was ablated in 24/24 limbs in groups SR and SP and the % 
      improvement in AVVSS was 83% (median 14.4 (IQR 8.2-19.4) to 2.4 (1.9-4.6), p < 
      0.001, Mann-Whitney u-test) and 84% (median 13.8 (IQR 6.3-17.5) to 2.2 (1.2-5.1), 
      p < 0.001) respectively (p = 0.33). These improvements persisted at 1 year 
      follow-up. A further 29 limbs with isolated anterior accessory great saphenous 
      vein (AAGSV) or segmental GSV/SSV reflux were successfully ablated. Complication 
      rates for primary and RVVS were similar. CONCLUSIONS: EVLA is a safe and 
      effective option for the treatment of RVVS and could be a preferred option for 
      suitable patients.
CI  - Copyright (c) 2011 European Society for Vascular Surgery. Published by Elsevier 
      Ltd. All rights reserved.
FAU - Theivacumar, N S
AU  - Theivacumar NS
AD  - Leeds Vascular Institute, The General Infirmary at Leeds, Leeds LS1 3EX, United 
      Kingdom.
FAU - Gough, M J
AU  - Gough MJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110226
PL  - England
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official journal of 
      the European Society for Vascular Surgery
JID - 9512728
SB  - IM
MH  - Adult
MH  - Aged
MH  - Endovascular Procedures/*methods
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Laser Therapy
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Ultrasonography
MH  - Varicose Veins/diagnostic imaging/*surgery
EDAT- 2011/03/01 06:00
MHDA- 2011/06/29 06:00
CRDT- 2011/03/01 06:00
PHST- 2010/10/24 00:00 [received]
PHST- 2011/01/09 00:00 [accepted]
PHST- 2011/03/01 06:00 [entrez]
PHST- 2011/03/01 06:00 [pubmed]
PHST- 2011/06/29 06:00 [medline]
AID - S1078-5884(11)00053-0 [pii]
AID - 10.1016/j.ejvs.2011.01.018 [doi]
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 2011 May;41(5):691-6. doi: 10.1016/j.ejvs.2011.01.018. 
      Epub 2011 Feb 26.